From Barchart: 2025-05-09 15:41:00

ICU Medical (NASDAQ:ICUI) reported Q1 CY2025 results, with sales up 5.8% year on year to $599.5 million and non-GAAP profit of $1.72 per share, 34.4% above estimates. The company saw growth across all core segments, driven by consumables, infusion systems, and vital care. Management cited momentum in oncology and home infusion markets. Looking ahead, ICU Medical plans to offset tariff costs and continue investing in pump innovation and compliance initiatives for reliable revenue growth. Analysts are monitoring customer adoption of new infusion pumps, effectiveness of tariff mitigation strategies, and regulatory progress on legacy product lines for future performance.



Read more at Barchart: Product Upgrades and Tariff Headwinds Shape Outlook